Clinical Trials Browser

OTHER × Leukemia, B-Cell × fludarabine × Clear all

Lymphoma, Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell

NCT03852407 2022-10-12

HLA

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, B-Cell, Hematologic Neoplasms

NCT03302403 2020-10-08

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

Phase NA Unknown

18 enrolled

GastrointestinalLymphoidOther hematologic neoplasmPlasma cell

Carcinoma, Hepatocellular, Pancreatic Neoplasms, Leukemia, B-Cell, Lymphoma, B-Cell, Neoplasms, Plasma Cell

NCT00714259 2017-07-24

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Phase 2/3 Terminated

5 enrolled 11 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, B-Cell, Lymphoma, Mantle-Cell

NCT00230282 2014-10-06

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Phase 2 Completed

25 enrolled 7 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

HLA

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia